12,372 trials
Diabetic Neuropathy
Primary: Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period…
Advanced Stage Parkinson's Disease
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 357 Subjects
Idiopathic Parkinson's Disease
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 170 Subjects
Abscess · Wound Infection · Diabetic Foot
Primary: Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population — 88.6; 89.6 percentage of…
Arthritis, Juvenile Idiopathic
Primary: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase — 13; 20 Participants — p=0.031
Hepatitis A Virus Infection
Primary: Hepatitis A Virus (HAV) Seroconversion Rate, i.e. the Percentage of Subjects Who Were Seronegative at Baseline and Developed Seropositive at Month 7 After Administration…
Psoriasis
Primary: Number of Participants With a 50% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI50 Response) — 78; 54; 80; 55…
Atelectasis
Primary: Oxygen Requirement to Maintain SpO2>90% — 1; 1; 1; 1 liters per minute
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
Gastroesophageal Reflux
Primary: Number of Patients Withdrawn From Study Due to Lack of Efficacy. — 6; 6 patients — p=1.0
Crohn's Disease
Primary: Percentage of Subjects Achieving Clinical Remission — 69.5 Percentage of participants
Gastroesophageal Reflux
Primary: Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period — 0; 3; 0; 1 patients
Renal Transplant
Primary: Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation. — 12 patients
Hepatitis B · Chronic Disease
Primary: Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12 — -6.23; -4.52 log10 copies/mL
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain — 2.65; 0.51; 3.89 T-Score